Ruzasvir

DRUG7 trials

Sponsors

Atea Pharmaceuticals Inc., Merck Sharp & Dohme LLC, Atea Pharmaceuticals, Inc.

Conditions

Chronic Hepatitis C VirusChronic Hepatitis C Virus (HCV) InfectionHCVHepatic CirrhosisHepatitis CHepatitis C InfectionHepatitis C, Chronic

Phase 1

Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

CompletedNCT02076100

Merck Sharp & Dohme LLCHepatitis C Infection

Start: 2014-03-27End: 2015-11-15Updated: 2018-12-24

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

CompletedNCT02666352

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2016-01-22End: 2017-01-16Updated: 2018-09-17

Phase 2

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

CompletedNCT02332720

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-28End: 2017-05-03Updated: 2019-07-30

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

CompletedNCT02332707

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-22End: 2016-12-06Updated: 2019-07-23

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

TerminatedNCT02956629

Merck Sharp & Dohme LLCHepatitis C

Start: 2016-11-16End: 2018-03-05Updated: 2021-02-02

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

CompletedNCT05904470

Atea Pharmaceuticals, Inc.Chronic Hepatitis C Virus, HCV, Hepatic Cirrhosis +2

Start: 2023-05-30End: 2025-01-28Updated: 2025-10-21

A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

CompletedCTIS2023-504566-28-00

Atea Pharmaceuticals Inc.Chronic Hepatitis C Virus (HCV) Infection

Start: 2023-05-19End: 2025-01-28Target: 39Updated: 2024-04-22

Related Papers

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

2019-07-119 citations

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

2017-08-1018 citations

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

2017-08-1012 citations